Atrix Leuprogel
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Interim data from the first 51 of 120 prostate cancer patients to complete a pivotal Phase III trial of 30-day sustained release leuprolide acetate showed that it was "effective in reducing testosterone well below castrate levels with a corresponding positive response in [serum prostate specific antigen] values," according to a study abstract. Atrix plans to file an NDA for treatment of advanced prostate cancer during the first half of 2001. Atrix is enrolling patients for a trial of 90-day Leuprogel, and will follow that study with a trial of a 120-day formulation, the company sai
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.